Breathe Well Live Well
|
Regeneron speeds toward the FDA with its would-be asthma blockbuster
FierceBiotech Meanwhile, after meeting with the FDA, Regeneron now believes the agency will recognize an earlier Phase IIb asthma study as one of two required pivotal trials. In that trial, the highest doses of dupilumab significantly beat out placebo in improving … Regeneron and Sanofi Announce Positive Pivotal Phase 2b Dupilumab Data in … |
View full post on asthma – Google News
|
Regeneron and Sanofi Announce Positive Pivotal Phase 2b Dupilumab Data in …
Benzinga Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today shared positive results from an interim analysis of a pivotal Phase 2b study of dupilumab in adult patients with moderate-to-severe asthma, who are uncontrolled despite treatment with … |
View full post on asthma – Google News
Reuters |
Promising asthma trial prompts Regeneron, Sanofi to push dupilumab into PhIII
FierceBiotech Regeneron and its close partner Sanofi have cleared the final mid-stage hurdle for dupilumab in asthma patients, with several doses hitting the trial endpoint both for a subset of patients as well as the broad population. And the ambitious development … Sanofi's dual-action biotech asthma drug performs well in test Positive results for Sanofi/Regeneron's dupilumab in asthma |
View full post on asthma – Google News
|
Biocentury: Regeneron using Interleukin Antibody Receptors for Asthma …
OneMedPlace (blog) An estimated 25 million Americans suffer from Asthma, but current medications such as inhalers have been deemed ineffective for 10-20% of its users. Regneron (REGN) and Sanofi (SAN) have partnered to crease a new Asthma drug, Dupilumab. In their … Clearing The Air On The Sanofi-Regeneron Asthma Drug Trial |
View full post on asthma – Google News
|
Regeneron, Sanofi asthma drug seen as potential game changer
Reuters (Reuters) – A new type of asthma drug meant to attack the underlying causes of the respiratory disease slashed episodes by 87 percent in a mid-stage trial, making it a potential game changer for patients with moderate to severe disease, researchers … Monoclonal antibody appears effective and safe in asthma Phase IIa trial Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of … |
View full post on asthma – Google News